



Professor Peter Horby, Professor Martin Landray
RECOVERY trial Co-chairs
Nuffield Department of Population Health
Oxford

3rd December 2020

Dear Peter and Martin

RECOVERY trial DMC report

The RECOVERY trial DMC reviewed the safety and efficacy data that were available today for the 19,260 patients randomised. For the interventions still in active recruitment, the numbers included in the comparison of each agent with its control were respectively: convalescent plasma (5,421), tocilizumab (2,079), REGN-COV2 (1,231), aspirin (1,585) and colchicine (114).

In the light of these data and all available external information, we saw no cogent reason to modify the protocol or intake to the study.

We recommend continuing recruitment of eligible patients to all active arms of the trial. The DMC will next meet on 17th December 2020.

Yours sincerely

Professor Peter Sandercock, MA, DM, FRCPE, FESO, FWSO
Chairman RECOVERY trial DMC
Emeritus Professor of Medical Neurology, Centre for Clinical Brain Sciences

Cc DMC members, RECOVERY trial office.

CENTRE DIRECTOR Professor S Chandran
Professor M Dennis Professor A Farrall Professor S Grant Professor J Ironside Professor R Knight Professor S Lawrie
Professor A McIntosh Professor M Macleod Professor I Marshall Professor D Owens Professor C Ritchie Professor P Sandercock
Professor R Sellar Professor C Smith Professor C Sudlow Professor L Thomson Professor A Waldman Professor J Wardlaw Professor R Will

The University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK
t: +44 (0)131 465 9602 / w: www.ccbs.ed.ac.uk / e: Peter.sandercock@ed.ac.uk

